Olanzapine compared to quetiapine in adolescents with a first psychotic episode




Es wurden keine entsprechenden Inhalte gefunden.

Details zur Publikation

Autorenliste: Bombin I
Verlag: Springer (part of Springer Nature): Springer Open Choice Hybrid Journals
Jahr der Veröffentlichung: 2009
Bandnummer: 18
Heftnummer: 7
Erste Seite: 418
Letzte Seite: 428
Seitenumfang: 11
ISSN: 1018-8827
Sprachen: Englisch-Vereinigtes Königreich (EN-GB)


Objective: To compare the efficacy, safety, and tolerability of
olanzapine and quetiapine in adolescents with first episode psychosis.
Method: Fifty adolescents (age 16 ± 1.25) with a first episode of
psychosis were randomized to quetiapine or olanzapine in a 6-month open
label study. Efficacy and side effect scales, as well as vital signs and
laboratory data were recorded at baseline, 7, 15, 30, 90, and 180 days
(end of study). Results: Out of the total sample included in the study,
32 patients completed the trial (quetiapine n = 16, olanzapine n = 16).
Patients in both treatment groups had a significant reduction in all
clinical scales with the exception of the negative scale of the Positive
and Negative Symptom Scale (PANSS) for olanzapine and the general
psychopathology scale of the PANSS for quetiapine. The only difference
between treatment arms on the clinical scales was observed on the
patients' strength and difficulties questionnaire (SDQ) scale, with
greater improvement for olanzapine. Patients on olanzapine gained 15.5
kg and patients on quetiapine gained 5.5 kg. Conclusion: Olanzapine and
quetiapine reduced psychotic symptoms in this adolescent sample.
Patients on olanzapine gained significantly more weight. Side effects
with both drugs seemed to be more prevalent than those reported in adult


Es wurden keine entsprechenden Inhalte gefunden.


Es wurden keine entsprechenden Inhalte gefunden.

Zuletzt aktualisiert 2019-13-08 um 00:45